



The FDA Safety Information and
Adverse Event Reporting Program

DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain

[Posted 08/28/2015]

FDA 提出警告，表示第二型糖尿病治療藥物中的 dipeptidyl peptidase-4 (DPP-4) inhibitors (如 sitagliptin, saxagliptin, linagliptin, alogliptin) 可能導致服藥者關節疼痛，嚴重者可能無法行動。FDA 已在此類藥品標籤加註相關警語與注意事項。

建議

FDA 建議，已使用 DPP-4 抑制劑的患者不應自行停藥，但服藥期間若發生嚴重或持久性關節疼痛必須立即與醫療人員聯絡，醫療人員須考量 DPP-4 抑制劑引起嚴重關節疼痛的可能性，如情況許可應停止用藥。

[Posted 08/28/2015]

AUDIENCE: Patient, Endocrinology, Family Practice, Internal Medicine

ISSUE: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. See the [Drug Safety Communication](#) for a complete list of all FDA-approved DPP-4 inhibitors.

BACKGROUND: DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. These medicines are available as single-ingredient products and in combination with other diabetes medicines such as metformin.

RECOMMENDATION: Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right away if they experience severe and persistent joint pain. Health care professionals should consider DPP-4 inhibitors as a possible cause of severe joint pain and discontinue the drug if appropriate.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report Online: www.fda.gov/MedWatch/report

[Download form](#) or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

Read the MedWatch Safety Alert, including a link to the Drug Safety Communication, at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm>

Table 1. List of FDA-approved DPP-4 inhibitors

Brand name	Active ingredient(s)
Januvia	sitagliptin
Janumet	sitagliptin and metformin
Janumet XR	sitagliptin and metformin extended release
Onglyza	saxagliptin
Kombiglyze XR	saxagliptin and metformin extended release
Tradjenta	linagliptin
Glyxambi	linagliptin and empagliflozin
Jentadueto	linagliptin and metformin
Nesina	alogliptin
Kazano	alogliptin and metformin
Oseni	alogliptin and pioglitazone